Skip to content
MARKETS / NASDAQ / NEPH
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Nephros Inc. NEPH

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$18.8M
▲ 32.7% YoY
$1.2M
▲ 1513.5% YoY
In brief

What this company does

Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration. Our medical filtration portfolio includes two product lines: infection control and dialysis water. All of our medical-grade filters are FDA 510(k)-cleared as Class II medical devices—a distinguishing feature that affirms their validated safety and performance in critical-use environments. We develop and sell point-of-use water filtration products used in both medical and commercial applications.

Written from the business description in Nephros, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth
USD 18.8M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 18.8 · Net income 1.2
8.0M16.0M-2.5M-5.0M200920112013201520172019202120232025
Compound annual growth
+23.5%
+17.0%
+25.5%
+13.2%
−7.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
6 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 6.1% · Net 6.4%
50%100%-200%-400%200920112013201520172019202120232025
ROE
FY2024 · ROE 0.9%
100%200%300%-500%-1000%-1500%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -0.5
-2.5M-5.0M200920112013201520172019202120232025

Total assetsUSD 13.6M
CashUSD 5.4M
Current ratio4.06×

Not available: we don't have the total debt figure for this period.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0·
Operating income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B0.00.00.00.00.0·−0.0−0.0−0.0········
Net income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.00.0−0.0
Free cash flow $B·−0.00.0−0.0−0.0−0.0−0.0··−0.0−0.0·−0.0−0.0·−0.0·
EPS, diluted $0.110.01−0.15−0.73−0.41−0.52−0.45−0.50−0.02−0.06−0.09−0.31−0.18−0.59−0.811.86−6.32
Dividend / sh $·················
Payout %·················
ROE %·0.9−22.6−82.2−31.9−52.6−75.0−118.4−61.8····−1603.6−899.5370.8−617.1
Shares out B0.010.010.010.010.010.010.010.010.060.050.050.030.020.010.010.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 79 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image